Synchrony's Clarus veterinary financing deal draws analyst attention
Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash
Synchrony Financial reported Q3 2026 net interest income of US$4,809 million and net income of US$892 million. A new partnership with Clarus Technology embeds financing and insurance insights into veterinary workflows, expanding the company's healthcare financing reach. Analysts carry a US$86.83 target versus a US$75.35 price, with 16 Buy, 7 Hold and no Sell ratings.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.